Mylan announced that it is planning to launch two new low-cost HIV combination treatments in the U.S market.
FDA recently approved Symfi Lo, a three-drug single-tablet antiretroviral regimen, and Cimduo, a double combination, for HIV treatment.
Symfi Lo, which Mylan has been selling overseas since March 2017, will be available in the coming weeks whereas Cimduo is expected in the second quarter of 2018.
According to Mylan, in order to help reduce the high cost of HIV treatment in the U.S, Symfi Lo's list price will be discounted significantly from the wholesale acquisition cost of any other STR on the U.S. market. Cimduo's list price will likewise be at a significant discount to any other tenofovir-based double combination product on the U.S. market.
Read the Mylan press release